Sirtex Medical announces collaboration update with OncoSec Medical

Sirtex Medical announces collaboration update with OncoSec Medical
News provided by
Share this article
 TAVO™ for the treatment of advanced melanoma
WOBURN, Mass., Jan. 19, 2021 /PRNewswire/ --
Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec's lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO™ and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec. 

Related Keywords

Australia ,United States ,Danielj Oconnor ,Kevinr Smith , ,Exchange Commission ,Oncosec Medical Inc ,Sirtex Pty Ltd ,Sirtex Medical Us Holdings Inc ,Nasdaq ,Oncosec Medical ,Biologics License Application ,Chief Executive Officer ,Visceral Lesion Applicator ,Spheres Pty ,Sirtex ,ஆஸ்திரேலியா ,ஒன்றுபட்டது மாநிலங்களில் ,பரிமாற்றம் தரகு ,சிர்தெக்ஷ ப்டி லிமிடெட் ,சிர்தெக்ஷ மருத்துவ எங்களுக்கு ஹோல்டிங்ஸ் இன்க் ,நாஸ்டாக் ,உயிரியல் உரிமம் விண்ணப்பம் ,தலைமை நிர்வாகி அதிகாரி ,கோளங்கள் ப்டி ,சிர்தெக்ஷ ,